SrasV1, PubMed, Checkpoint, bibRecord, 000E90

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.

Identifieur interne : 000E90 ( PubMed/Checkpoint ); précédent : 000E89; suivant : 000E91

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.

Auteurs : Rudragouda Channappanavar [États-Unis] ; Craig Fett [États-Unis] ; Jincun Zhao [États-Unis] ; David K. Meyerholz [États-Unis] ; Stanley Perlman [États-Unis]

Source :

Journal of virology [ 1098-5514 ] ; 2014.

RBID : pubmed:25056892

Descripteurs français

KwdFr :
- Analyse de survie, Animaux, Anticorps antiviraux (biosynthèse), Antigènes viraux (), Antigènes viraux (génétique), Antigènes viraux (immunologie), Cellules dendritiques (immunologie), Cellules dendritiques (transplantation), Cellules dendritiques (virologie), Déterminants antigéniques des lymphocytes T (génétique), Déterminants antigéniques des lymphocytes T (immunologie), Expression des gènes, Femelle, Humains, Immunisation, Immunité active, Immunité cellulaire (), Immunité humorale (), Lymphocytes T CD4+ (immunologie), Lymphocytes T CD4+ (virologie), Lymphocytes T CD8+ (immunologie), Lymphocytes T CD8+ (virologie), Mémoire immunologique, Peptides (administration et posologie), Peptides (génétique), Peptides (immunologie), Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (mortalité), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
MESH :
- administration et posologie : Peptides.
- biosynthèse : Anticorps antiviraux.
- génétique : Antigènes viraux, Déterminants antigéniques des lymphocytes T, Peptides.
- immunologie : Antigènes viraux, Cellules dendritiques, Déterminants antigéniques des lymphocytes T, Lymphocytes T CD4+, Lymphocytes T CD8+, Peptides, Syndrome respiratoire aigu sévère, Virus du SRAS.
- mortalité : Syndrome respiratoire aigu sévère.
- pathogénicité : Virus du SRAS.
- virologie : Cellules dendritiques, Lymphocytes T CD4+, Lymphocytes T CD8+, Syndrome respiratoire aigu sévère.
- Analyse de survie, Animaux, Antigènes viraux, Cellules dendritiques, Expression des gènes, Femelle, Humains, Immunisation, Immunité active, Immunité cellulaire, Immunité humorale, Mémoire immunologique, Souris, Syndrome respiratoire aigu sévère.

English descriptors

KwdEn :
- Animals, Antibodies, Viral (biosynthesis), Antigens, Viral (chemistry), Antigens, Viral (genetics), Antigens, Viral (immunology), CD4-Positive T-Lymphocytes (immunology), CD4-Positive T-Lymphocytes (virology), CD8-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (virology), Dendritic Cells (immunology), Dendritic Cells (transplantation), Dendritic Cells (virology), Epitopes, T-Lymphocyte (genetics), Epitopes, T-Lymphocyte (immunology), Female, Gene Expression, Humans, Immunity, Active, Immunity, Cellular (drug effects), Immunity, Humoral (drug effects), Immunization, Immunologic Memory, Mice, Peptides (administration & dosage), Peptides (genetics), Peptides (immunology), SARS Virus (immunology), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (mortality), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Survival Analysis.
MESH :
- chemical , administration & dosage : Peptides.
- chemical , biosynthesis : Antibodies, Viral.
- chemical , chemistry : Antigens, Viral.
- chemical , genetics : Antigens, Viral, Epitopes, T-Lymphocyte, Peptides.
- chemical , immunology : Antigens, Viral, Epitopes, T-Lymphocyte, Peptides.
- drug effects : Immunity, Cellular, Immunity, Humoral.
- immunology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Dendritic Cells, SARS Virus, Severe Acute Respiratory Syndrome.
- mortality : Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- transplantation : Dendritic Cells.
- virology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Dendritic Cells, Severe Acute Respiratory Syndrome.
- Animals, Female, Gene Expression, Humans, Immunity, Active, Immunization, Immunologic Memory, Mice, Survival Analysis.

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) caused an acute human respiratory illness with high morbidity and mortality in 2002-2003. Several studies have demonstrated the role of neutralizing antibodies induced by the spike (S) glycoprotein in protecting susceptible hosts from lethal infection. However, the anti-SARS-CoV antibody response is short-lived in patients who have recovered from SARS, making it critical to develop additional vaccine strategies. SARS-CoV-specific memory CD8 T cells persisted for up to 6 years after SARS-CoV infection, a time at which memory B cells and antivirus antibodies were undetectable in individuals who had recovered from SARS. In this study, we assessed the ability of virus-specific memory CD8 T cells to mediate protection against infection in the absence of SARS-CoV-specific memory CD4 T or B cells. We demonstrate that memory CD8 T cells specific for a single immunodominant epitope (S436 or S525) substantially protected 8- to 10-month-old mice from lethal SARS-CoV infection. Intravenous immunization with peptide-loaded dendritic cells (DCs) followed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in accumulation of virus-specific memory CD8 T cells in bronchoalveolar lavage fluid (BAL), lungs, and spleen. Upon challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced multiple effector cytokines (gamma interferon [IFN-γ], tumor necrosis factor alpha [TNF-α], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme B) and reduced lung viral loads. Overall, our results show that SARS-CoV-specific memory CD8 T cells protect susceptible hosts from lethal SARS-CoV infection, but they also suggest that SARS-CoV-specific CD4 T cell and antibody responses are necessary for complete protection.

DOI: 10.1128/JVI.01505-14
PubMed: 25056892

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000F59
to stream PubMed, to step Curation: 000F59

Links to Exploration step

pubmed:25056892

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.</title>
<author><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Fett, Craig" sort="Fett, Craig" uniqKey="Fett C" first="Craig" last="Fett">Craig Fett</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Meyerholz, David K" sort="Meyerholz, David K" uniqKey="Meyerholz D" first="David K" last="Meyerholz">David K. Meyerholz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA Stanley-perlman@uiowa.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25056892</idno>
<idno type="pmid">25056892</idno>
<idno type="doi">10.1128/JVI.01505-14</idno>
<idno type="wicri:Area/PubMed/Corpus">000F59</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F59</idno>
<idno type="wicri:Area/PubMed/Curation">000F59</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F59</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000E90</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E90</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.</title>
<author><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Fett, Craig" sort="Fett, Craig" uniqKey="Fett C" first="Craig" last="Fett">Craig Fett</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Meyerholz, David K" sort="Meyerholz, David K" uniqKey="Meyerholz D" first="David K" last="Meyerholz">David K. Meyerholz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pathology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
<author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA Stanley-perlman@uiowa.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
<placeName><region type="state">Iowa</region>
<settlement type="city">Iowa City</settlement>
</placeName>
<orgName type="university">Université de l'Iowa</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (biosynthesis)</term>
<term>Antigens, Viral (chemistry)</term>
<term>Antigens, Viral (genetics)</term>
<term>Antigens, Viral (immunology)</term>
<term>CD4-Positive T-Lymphocytes (immunology)</term>
<term>CD4-Positive T-Lymphocytes (virology)</term>
<term>CD8-Positive T-Lymphocytes (immunology)</term>
<term>CD8-Positive T-Lymphocytes (virology)</term>
<term>Dendritic Cells (immunology)</term>
<term>Dendritic Cells (transplantation)</term>
<term>Dendritic Cells (virology)</term>
<term>Epitopes, T-Lymphocyte (genetics)</term>
<term>Epitopes, T-Lymphocyte (immunology)</term>
<term>Female</term>
<term>Gene Expression</term>
<term>Humans</term>
<term>Immunity, Active</term>
<term>Immunity, Cellular (drug effects)</term>
<term>Immunity, Humoral (drug effects)</term>
<term>Immunization</term>
<term>Immunologic Memory</term>
<term>Mice</term>
<term>Peptides (administration & dosage)</term>
<term>Peptides (genetics)</term>
<term>Peptides (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>SARS Virus (pathogenicity)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (mortality)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Anticorps antiviraux (biosynthèse)</term>
<term>Antigènes viraux ()</term>
<term>Antigènes viraux (génétique)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Cellules dendritiques (immunologie)</term>
<term>Cellules dendritiques (transplantation)</term>
<term>Cellules dendritiques (virologie)</term>
<term>Déterminants antigéniques des lymphocytes T (génétique)</term>
<term>Déterminants antigéniques des lymphocytes T (immunologie)</term>
<term>Expression des gènes</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunisation</term>
<term>Immunité active</term>
<term>Immunité cellulaire ()</term>
<term>Immunité humorale ()</term>
<term>Lymphocytes T CD4+ (immunologie)</term>
<term>Lymphocytes T CD4+ (virologie)</term>
<term>Lymphocytes T CD8+ (immunologie)</term>
<term>Lymphocytes T CD8+ (virologie)</term>
<term>Mémoire immunologique</term>
<term>Peptides (administration et posologie)</term>
<term>Peptides (génétique)</term>
<term>Peptides (immunologie)</term>
<term>Souris</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (mortalité)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Virus du SRAS (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antigens, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term>
<term>Epitopes, T-Lymphocyte</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Viral</term>
<term>Epitopes, T-Lymphocyte</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Immunity, Cellular</term>
<term>Immunity, Humoral</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term>
<term>Déterminants antigéniques des lymphocytes T</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes viraux</term>
<term>Cellules dendritiques</term>
<term>Déterminants antigéniques des lymphocytes T</term>
<term>Lymphocytes T CD4+</term>
<term>Lymphocytes T CD8+</term>
<term>Peptides</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term>
<term>CD8-Positive T-Lymphocytes</term>
<term>Dendritic Cells</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Dendritic Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Cellules dendritiques</term>
<term>Lymphocytes T CD4+</term>
<term>Lymphocytes T CD8+</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term>
<term>CD8-Positive T-Lymphocytes</term>
<term>Dendritic Cells</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Gene Expression</term>
<term>Humans</term>
<term>Immunity, Active</term>
<term>Immunization</term>
<term>Immunologic Memory</term>
<term>Mice</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term>
<term>Animaux</term>
<term>Antigènes viraux</term>
<term>Cellules dendritiques</term>
<term>Expression des gènes</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunisation</term>
<term>Immunité active</term>
<term>Immunité cellulaire</term>
<term>Immunité humorale</term>
<term>Mémoire immunologique</term>
<term>Souris</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome coronavirus (SARS-CoV) caused an acute human respiratory illness with high morbidity and mortality in 2002-2003. Several studies have demonstrated the role of neutralizing antibodies induced by the spike (S) glycoprotein in protecting susceptible hosts from lethal infection. However, the anti-SARS-CoV antibody response is short-lived in patients who have recovered from SARS, making it critical to develop additional vaccine strategies. SARS-CoV-specific memory CD8 T cells persisted for up to 6 years after SARS-CoV infection, a time at which memory B cells and antivirus antibodies were undetectable in individuals who had recovered from SARS. In this study, we assessed the ability of virus-specific memory CD8 T cells to mediate protection against infection in the absence of SARS-CoV-specific memory CD4 T or B cells. We demonstrate that memory CD8 T cells specific for a single immunodominant epitope (S436 or S525) substantially protected 8- to 10-month-old mice from lethal SARS-CoV infection. Intravenous immunization with peptide-loaded dendritic cells (DCs) followed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in accumulation of virus-specific memory CD8 T cells in bronchoalveolar lavage fluid (BAL), lungs, and spleen. Upon challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced multiple effector cytokines (gamma interferon [IFN-γ], tumor necrosis factor alpha [TNF-α], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme B) and reduced lung viral loads. Overall, our results show that SARS-CoV-specific memory CD8 T cells protect susceptible hosts from lethal SARS-CoV infection, but they also suggest that SARS-CoV-specific CD4 T cell and antibody responses are necessary for complete protection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25056892</PMID>
<DateCompleted><Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>88</Volume>
<Issue>19</Issue>
<PubDate><Year>2014</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.</ArticleTitle>
<Pagination><MedlinePgn>11034-44</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.01505-14</ELocationID>
<Abstract><AbstractText Label="UNLABELLED">Severe acute respiratory syndrome coronavirus (SARS-CoV) caused an acute human respiratory illness with high morbidity and mortality in 2002-2003. Several studies have demonstrated the role of neutralizing antibodies induced by the spike (S) glycoprotein in protecting susceptible hosts from lethal infection. However, the anti-SARS-CoV antibody response is short-lived in patients who have recovered from SARS, making it critical to develop additional vaccine strategies. SARS-CoV-specific memory CD8 T cells persisted for up to 6 years after SARS-CoV infection, a time at which memory B cells and antivirus antibodies were undetectable in individuals who had recovered from SARS. In this study, we assessed the ability of virus-specific memory CD8 T cells to mediate protection against infection in the absence of SARS-CoV-specific memory CD4 T or B cells. We demonstrate that memory CD8 T cells specific for a single immunodominant epitope (S436 or S525) substantially protected 8- to 10-month-old mice from lethal SARS-CoV infection. Intravenous immunization with peptide-loaded dendritic cells (DCs) followed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in accumulation of virus-specific memory CD8 T cells in bronchoalveolar lavage fluid (BAL), lungs, and spleen. Upon challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced multiple effector cytokines (gamma interferon [IFN-γ], tumor necrosis factor alpha [TNF-α], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme B) and reduced lung viral loads. Overall, our results show that SARS-CoV-specific memory CD8 T cells protect susceptible hosts from lethal SARS-CoV infection, but they also suggest that SARS-CoV-specific CD4 T cell and antibody responses are necessary for complete protection.</AbstractText>
<AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Virus-specific CD8 T cells are required for pathogen clearance following primary SARS-CoV infection. However, the role of SARS-CoV-specific memory CD8 T cells in mediating protection after SARS-CoV challenge has not been previously investigated. In this study, using a prime-boost immunization approach, we showed that virus-specific CD8 T cells protect susceptible 8- to 10-month-old mice from lethal SARS-CoV challenge. Thus, future vaccines against emerging coronaviruses should emphasize the generation of a memory CD8 T cell response for optimal protection.</AbstractText>
<CopyrightInformation>Copyright © 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Channappanavar</LastName>
<ForeName>Rudragouda</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fett</LastName>
<ForeName>Craig</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Jincun</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Meyerholz</LastName>
<ForeName>David K</ForeName>
<Initials>DK</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, University of Iowa, Iowa City, Iowa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perlman</LastName>
<ForeName>Stanley</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA Stanley-perlman@uiowa.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>AI091322</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI091322</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI060699</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P01 AI060699</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 DK054759</GrantID>
<Acronym>DK</Acronym>
<Agency>NIDDK NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>07</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007110" MajorTopicYN="N">Immunity, Active</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007156" MajorTopicYN="Y">Immunologic Memory</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>7</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25056892</ArticleId>
<ArticleId IdType="pii">JVI.01505-14</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.01505-14</ArticleId>
<ArticleId IdType="pmc">PMC4178831</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2013 Jun;87(12):6551-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23576515</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2005 May;22(5):561-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15894274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Am Thorac Soc. 2005;2(2):126-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16113480</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2006 Jan 1;176(1):537-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16365448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2006 Aug;120(2):171-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16781892</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2006 Aug 1;351(2):466-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16690096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2006 Dec;3(12):e525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17194199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2007 Feb;81(4):1701-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17108030</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2007 Oct;88(Pt 10):2740-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17872527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2008 Jan 11;319(5860):198-202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18187654</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2013 Dec;11(12):836-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24217413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2013 Nov 14;39(5):939-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24238342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Leukoc Biol. 2014 Feb;95(2):215-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24006506</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24599590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2005 Apr 25;335(1):34-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15823604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2008 Feb;8(2):107-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18219309</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Apr;74(8):3486-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10729122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2000 May;12(5):451-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10843378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2000 Aug 15;165(4):2278-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10925317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2000 Sep 1;165(5):2404-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10946264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2000 Dec;74(24):11690-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11090168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2001 Feb 1;166(3):1813-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11160228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2003 Jul 1;171(1):27-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12816979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2003 Aug 4;198(3):399-410</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15242938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1990 Sep;64(9):4589-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2166833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Oct;13(10):1562-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18258008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2008 Apr;133(1):45-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17416434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2008 Apr;8(4):247-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18323851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2008 Aug 1;68(15):6341-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18676859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Immunol. 2009;27:61-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18954284</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2009 Aug 15;183(4):2337-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19635915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2009 Sep;83(18):9258-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19570864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Feb;84(3):1289-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2010 Jul 23;33(1):96-105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20637658</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Sep;84(18):9318-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20610717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Jun 15;186(12):7264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21576510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Dec 1;187(11):5510-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22058417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2011 Dec;121(12):4921-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22105170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2012 Dec;18(12):1820-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23142821</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2013 Mar;14(3):238-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23354485</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2013 Apr 15;190(8):3854-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23467935</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2013 May;14(5):509-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23542740</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Res. 2014 Aug;59(1-3):118-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24845462</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Iowa</li>
</region>
<settlement><li>Iowa City</li>
</settlement>
<orgName><li>Université de l'Iowa</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Iowa"><name sortKey="Channappanavar, Rudragouda" sort="Channappanavar, Rudragouda" uniqKey="Channappanavar R" first="Rudragouda" last="Channappanavar">Rudragouda Channappanavar</name>
</region>
<name sortKey="Fett, Craig" sort="Fett, Craig" uniqKey="Fett C" first="Craig" last="Fett">Craig Fett</name>
<name sortKey="Meyerholz, David K" sort="Meyerholz, David K" uniqKey="Meyerholz D" first="David K" last="Meyerholz">David K. Meyerholz</name>
<name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
<name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E90 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000E90 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:25056892
   |texte=   Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:25056892" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.

Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki